European Medicines Agency sees strong level of applications in 2007

European Medicines AgencyThe number of applications for marketing authorisations submitted to the European Medicines Agency (EMEA) remains strong according to the half-year report presented to the Agency's Management Board by Thomas Lönngren, EMEA Executive Director, at its 4 October 2007 meeting.

The Agency has received a total of 42 applications by mid-2007, with a further 52 forecast by the end of the year. This follows the record number of applications made to the Agency in 2006. One area of growth is applications for biosimilar medicines, with 8 applications made in the first half of 2007 and a further 8 expected by the end of the year.

Reviewing the Agency's implementation of the 2007 work programme, the Board highlighted two major achievements from the first half year. One is the Agency’s progress on implementing the new Paediatric Regulation, including the successful establishment of the Paediatric Committee (PDCO). The other is the roll-out of a new data analysis system for EudraVigilance, the European pharmacovigilance data-processing network management system, to all competent authorities in the EU Member States, which has significantly improved the systems capabilities to monitor the safety of medicines.

The Management Board also adopted the EU telematics master plan that aims to provide a coherent development strategy for 2007-2013 for EU telematics – the set of pan-European IT systems and databases used for the collection and dissemination of information on medicines in the European Union.

The second status report on the implementation of the EMEA road map to 2010 was presented to the Management Board and will be published on the EMEA website. The report highlights progress made in 2006 and the first half of 2007 in areas that include improving safety of medicines; stimulating research and innovation in partnership with European institutions; improving availability to medicines; strengthening the provision of information and interaction with Agency stakeholders; reinforcing international collaboration; and strengthening the European Union regulatory system for medicines. Stepping up the implementation, a new action plan is currently under preparation, which will set out the initiatives to be undertaken in 2008 and 2009.

For further information, please visit:
www.emea.europa.eu

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...